List of works - Michael Lauseker

A multi-state model approach for prediction in chronic myeloid leukaemia.

scientific article published on 03 December 2014

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

scientific article published on 18 November 2009

Analysis of cause of death: Competing risks or progressive illness-death model?

scientific article published on 25 January 2019

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

scientific article published on 14 August 2017

Chromogranin a as serum marker for gastroenteropancreatic neuroendocrine tumors: a single center experience and literature review

scientific article published on 15 February 2012

Combination of 13-Cis retinoic acid and lovastatin: marked antitumor potential in vivo in a pheochromocytoma allograft model in female athymic nude mice

scientific article

Comment on "Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed" Haematologica 2011;96(12):1779-82 ⬇️

scientific article published on May 1, 2012

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

scientific article

Differences in treatment and monitoring of chronic myeloid leukemia with regard to age, but not sex: Results from a population-based study

scientific article published on 28 August 2019

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib

scientific article

Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.

scientific article published on 17 September 2015

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

scientific article

Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase

scientific article published on 22 June 2014

Estimating the distribution of heterogeneous treatment effects from treatment responses and from a predictive biomarker in a parallel-group RCT: A structural model approach

scientific article published on 04 March 2020

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.

scientific article published on 28 October 2011

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.

scientific article

Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.

scientific article published on 18 September 2015

Improved survival boosts the prevalence of chronic myeloid leukemia: predictions from a population-based study.

scientific article published on 16 April 2016

Influence of somatic mutations and pretransplant strategies in patients allografted for myelodysplastic syndrome or secondary acute myeloid leukemia

scientific article published on 05 October 2020

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.

scientific article published on 21 December 2012

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.

scientific article

Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin

scientific article published on 14 September 2019

Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death.

scientific article published on 27 March 2015

Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

scientific article published in 2021

Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia

scientific article published on 20 May 2011

Reflections on the true nature of spatial clusters in myelodysplastic syndromes

scientific article published on 08 October 2015

Remission status should not be treated as a base-line covariate--reply to Etienne et al.

scientific article published in September 2014

Reply to H. Kantarjian et al.

scientific article

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

scientific article

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.

scientific article published on 09 February 2016

Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death

scientific article published on 13 February 2017

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study.

scientific article published on 13 January 2012

Targeted antibiotic treatment of lame sheep with footrot using either oxytetracycline or gamithromycin

scientific article published on 20 December 2013

The impact of health care settings on survival time of patients with chronic myeloid leukemia

scientific article published on 12 March 2014

The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.

scientific article

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia

scientific article published on 21 March 2011

Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study

scientific article

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.

scientific article

Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.

scientific article published on 27 October 2013

List of works by Michael Lauseker

A multi-state model approach for prediction in chronic myeloid leukaemia.

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

Analysis of cause of death: Competing risks or progressive illness-death model?

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Chromogranin a as serum marker for gastroenteropancreatic neuroendocrine tumors: a single center experience and literature review

Combination of 13-Cis retinoic acid and lovastatin: marked antitumor potential in vivo in a pheochromocytoma allograft model in female athymic nude mice

Comment on "Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed" Haematologica 2011;96(12):1779-82 ⬇️

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

Differences in treatment and monitoring of chronic myeloid leukemia with regard to age, but not sex: Results from a population-based study

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib

Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase

Estimating the distribution of heterogeneous treatment effects from treatment responses and from a predictive biomarker in a parallel-group RCT: A structural model approach

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.

Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.

Improved survival boosts the prevalence of chronic myeloid leukemia: predictions from a population-based study.

Influence of somatic mutations and pretransplant strategies in patients allografted for myelodysplastic syndrome or secondary acute myeloid leukemia

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.

Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin

Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death.

Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia

Reflections on the true nature of spatial clusters in myelodysplastic syndromes

Remission status should not be treated as a base-line covariate--reply to Etienne et al.

Reply to H. Kantarjian et al.

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.

Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study.

Targeted antibiotic treatment of lame sheep with footrot using either oxytetracycline or gamithromycin

The impact of health care settings on survival time of patients with chronic myeloid leukemia

The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia

Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.

Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.